Last $89.52 USD
Change Today -0.29 / -0.32%
Volume 915.4K
NVS On Other Exchanges
Symbol
Exchange
SIX Swiss Ex
Xetra
New York
OTC US
Mexico
Frankfurt
SIX Swiss Ex
As of 8:04 PM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

Lichtstrasse 35

Basel, 4056

Switzerland

Phone: 41 61 324 11 11

Fax:

he prevention of osteoporosis in postmenopausal women. Zoledronic acid, the active ingredient in Reclast/Aclasta, is also approved in a number of countries in a different dosage under the trade name Zometa for certain oncology indications. Reclast/Aclasta is facing generic competition following patent expirations in 2013 on its active ingredient, zoledronic acid, in the U.S. and other major markets. Specialty Care Ophthalmology Lucentis (ranibizumab) is a recombinant humanized antibody fragment that binds to vascular endothelial growth factors (VEGF). It is an anti-VEGF therapy licensed in various countries for three ocular indications, including wet age-related macular degeneration (wet AMD), visual impairment due to diabetic macular edema (DME), and visual impairment due to macular edema secondary to retinal vein occlusion (RVO). Lucentis is approved in approximately 100 countries to treat patients with wet AMD, for the treatment of visual impairment due to DME and macular edema secondary to RVO. Also, Lucentis is licensed in approximately 40 countries for the treatment of visual impairment due to myopic CNV. The company licensed Lucentis from Genentech for development and commercialization outside of the U.S. Neuroscience Gilenya (fingolimod) is the first in a new class of multiple sclerosis (MS) therapies called sphingosine 1-phosphate receptor modulators and the first oral therapy approved to treat relapsing-remitting MS (RRMS). In the U.S., Gilenya is indicated for relapsing forms of MS. In the EU, Gilenya is indicated for adult patients with RRMS defined as either high disease activity despite treatment with beta interferon, or rapidly evolving severe RRMS. Gilenya is approved in approximately 75 countries worldwide. Gilenya is licensed from Mitsubishi Tanabe Pharma Corporation. Exelon (rivastigmine tartrate) and Exelon Patch (rivastigmine transdermal system) are cholinesterase inhibitors indicated for the treatment of Alzheimer's disease (AD) dementia and Parkinson's disease (PD) dementia. Exelon capsules are available to treat mild to moderate AD dementia in approximately 90 countries. Exelon is the cholinesterase inhibitor to be approved for mild to moderate PD dementia in addition to AD in both the U.S. and the EU. Exelon Patch is approved for the treatment of mild to moderate AD in approximately 85 countries, including approximately 20 countries where it is also approved for PD dementia. Comtan and Stalevo (entacapone and carbidopa, and levodopa and entacapone) are indicated for the treatment of PD. Stalevo (carbidopa, levodopa, and entacapone) is indicated for certain PD patients who experience end-of-dose motor (or movement) fluctuations, known as ‘wearing off’. Stalevo is available from the company in approximately 50 countries. Integrated Hospital Care Neoral (cyclosporine, USP Modified) is an immunosuppressant to prevent organ rejection following a kidney, liver, or heart transplant. Neoral is also approved for use in lung transplant in various countries outside of the U.S. This micro-emulsion formulation of cyclosporine is also indicated for treating selected autoimmune disorders, such as psoriasis and rheumatoid arthritis. Myfortic (enteric-coated formulation of mycophenolate sodium) is approved in approximately 90 countries for the prevention of acute rejection of kidney allografts, and is indicated in combination with cyclosporine and corticosteroids. Zortress/Certican (everolimus) is an oral inhibitor of the mTOR pathway, indicated to prevent organ rejection following solid organ transplantation. Zortress/Certican has been extensively studied as an immunosuppressant agent in solid organ transplantation with approximately 10,000 transplant recipients enrolled in Novartis-sponsored clinical trials worldwide. Under the trade name Certican, it is approved in approximately 90 countries to prevent organ rejection for renal and heart transplant patients, and in addition, in approximately 50 countries worldwide to prevent organ rejection for liver transplant patients. In the U.S., under the trade name Zortress, the drug is approved for the prophylaxis of organ rejection in ad

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVS:US $89.52 USD -0.29

NVS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Merck & Co Inc $58.44 USD -0.14
Nestle SA SFr.68.45 CHF 0.00
Pfizer Inc $30.07 USD +0.07
Roche Holding AG SFr.262.70 CHF +0.50
Procter & Gamble Co/The $81.16 USD -0.45
View Industry Companies
 

Industry Analysis

NVS

Industry Average

Valuation NVS Industry Range
Price/Earnings 22.8x
Price/Sales 3.7x
Price/Book 3.1x
Price/Cash Flow 24.9x
TEV/Sales 3.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVARTIS AG-ADR, please visit www.novartis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.